Back to Journals » Biologics: Targets and Therapy » Volume 6 » default

Biologics: Targets and Therapy


Archived Journals

Archive: Volume 6, 2012

Clofilium inhibits Slick and Slack potassium channels

Tejada MA, Stolpe K, Meinild AK, Klaerke DA

Biologics: Targets and Therapy 2012, 6:465-470

Published Date: 13 December 2012

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ

Biologics: Targets and Therapy 2012, 6:417-427

Published Date: 3 December 2012

Limited cross-reactivity of mouse monoclonal antibodies against Dengue virus capsid protein among four serotypes

Noda M, Masrinoul P, Punkum C, Pipattanaboon C, Ramasoota P, Setthapramote C, Sasaki T, Sasayama M, Yamashita A, Kurosu T, Ikuta K, Okabayashi T

Biologics: Targets and Therapy 2012, 6:409-416

Published Date: 26 November 2012

Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

Smaldone MC, Chen DY, Yu JQ, Plimack ER

Biologics: Targets and Therapy 2012, 6:395-407

Published Date: 19 November 2012

Role of CD44 as a marker of cancer stem cells in head and neck cancer

Trapasso S, Allegra E

Biologics: Targets and Therapy 2012, 6:379-383

Published Date: 1 November 2012

Clinical use of biologics in vasculitis syndromes

Paroli M

Biologics: Targets and Therapy 2012, 6:371-378

Published Date: 25 October 2012

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir

D'Ambrosio R, Aghemo A, Colombo M

Biologics: Targets and Therapy 2012, 6:363-370

Published Date: 18 October 2012

Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection

Ippoliti G, D'Armini AM, Lucioni M, Marjieh M, Viganò M

Biologics: Targets and Therapy 2012, 6:355-362

Published Date: 4 October 2012

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

Wiesik-Szewczyk E, Olesinska M

Biologics: Targets and Therapy 2012, 6:347-354

Published Date: 26 September 2012

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

The role of epigenetic mechanisms and processes in autoimmune disorders

Greer JM, McCombe PA

Biologics: Targets and Therapy 2012, 6:307-327

Published Date: 6 September 2012

OnabotulinumtoxinA in the treatment of neurogenic bladder

Gulamhusein A, Mangera A

Biologics: Targets and Therapy 2012, 6:299-306

Published Date: 28 August 2012

The molecular profile of luminal B breast cancer

Creighton CJ

Biologics: Targets and Therapy 2012, 6:289-297

Published Date: 24 August 2012

Castration-resistant prostate cancer: potential targets and therapies

Parray A, Siddique HR, Nanda S, Konety BR, Saleem M

Biologics: Targets and Therapy 2012, 6:267-276

Published Date: 17 August 2012

Emerging role of multikinase inhibitors for refractory thyroid cancer

Perez CA, Arango BA, Velez M, Raez LE, Santos ES

Biologics: Targets and Therapy 2012, 6:257-265

Published Date: 8 August 2012

New developments in the management of hepatitis C virus infection: focus on boceprevir

Berenguer M, López-Labrador FX

Biologics: Targets and Therapy 2012, 6:249-256

Published Date: 3 August 2012

Cetuximab and biomarkers in non-small-cell lung carcinoma

Patil N, Abba M, Allgayer H

Biologics: Targets and Therapy 2012, 6:221-231

Published Date: 13 July 2012

The effect of erythropoietin on normal and neoplastic cells

Elliott S, Sinclair AM

Biologics: Targets and Therapy 2012, 6:163-189

Published Date: 27 June 2012

Ovarian cancer: emerging molecular-targeted therapies

Sourbier C

Biologics: Targets and Therapy 2012, 6:147-154

Published Date: 20 June 2012

Metastatic gastric cancer – focus on targeted therapies

Meza-Junco J, Sawyer MB

Biologics: Targets and Therapy 2012, 6:137-146

Published Date: 20 June 2012

Exacerbation of collagen induced arthritis by Fcγ receptor targeted collagen peptide due to enhanced inflammatory chemokine and cytokine production

Szarka E, Neer Zs, Balogh P, Ádori M, Angyal A, Prechl J, Kiss E, Kövesdi D, Sármay G

Biologics: Targets and Therapy 2012, 6:101-115

Published Date: 12 April 2012

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab

Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M

Biologics: Targets and Therapy 2012, 6:83-87

Published Date: 11 April 2012

Natural killer cells: role in local tumor growth and metastasis

Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N

Biologics: Targets and Therapy 2012, 6:73-82

Published Date: 5 April 2012

Role of vandetanib in the management of medullary thyroid cancer

Brassard M, Rondeau G

Biologics: Targets and Therapy 2012, 6:59-66

Published Date: 8 March 2012

Stem cell-mediated osteogenesis: therapeutic potential for bone tissue engineering

Neman J, Hambrecht A, Cadry C, Jandial R

Biologics: Targets and Therapy 2012, 6:47-57

Published Date: 9 March 2012

Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis

Hasan E, Olusi S, Al-Awadhi A, Mokaddem K, Sharma P, George S

Biologics: Targets and Therapy 2012, 6:31-35

Published Date: 1 February 2012

Eribulin mesylate in the treatment of metastatic breast cancer

Jain S, Cigler T

Biologics: Targets and Therapy 2012, 6:21-29

Published Date: 11 January 2012

Monoclonal antibodies and Fc fragments for treating solid tumors

Eisenbeis AM, Grau SJ

Biologics: Targets and Therapy 2012, 6:13-20

Published Date: 5 January 2012

Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients

Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I

Biologics: Targets and Therapy 2012, 6:5-12

Published Date: 29 December 2011

Prevalence of OmpK35 and OmpK36 porin expression in beta-lactamase and non-beta-lactamase-producing Klebsiella pneumoniae

Shakib P, Ghafourian S, Zolfaghary MR, Hushmandfar R, Ranjbar R, Sadeghifard N

Biologics: Targets and Therapy 2012, 6:1-4

Published Date: 22 December 2011